Mirabegron therapy does not prevent progression to Heart Failure: Study

Written By : Isra Zaman

Medically Reviewed By : Dr. Kamal Kant Kohli

Published On 2023-09-25 04:00 GMT | Update On 2024-01-30 12:06 GMT

Mirabegron therapy showed no significant impact on left ventricular mass or diastolic function over 12 months in patients with structural heart disease and no or mild heart failure symptoms, a recent study published in JAMA Cardiology has found.

Left ventricular hypertrophy (LVH) is a significant contributor to heart failure (HF) development and progression. For individuals in the pre-HF stage (stage B), there has been a lack of effective treatments to prevent the transition to overt HF (stage C). A new study investigated whether activating β3-adrenergic receptors (β3ARs) using the β3AR agonist mirabegron could be a safe and effective approach to prevent the progression of LVH and diastolic dysfunction in patients with pre- or mild HF.

The Beta3-LVH trial, a prospective, triple-blind, placebo-controlled phase 2b randomized clinical trial, enrolled patients from September 12, 2016, to February 26, 2021, with a 12-month follow-up period. The trial randomized participants (1:1) to receive mirabegron (50 mg/d) or a placebo for 12 months.

Among the 296 enrolled patients, mirabegron had a neutral effect on LV mass and diastolic function over the 12-month study period. The mirabegron group showed a 1.3 g/m2 increase in LV mass index or LVMI and a −0.15 decrease in Doppler velocity ratio compared to the placebo group. Adverse events were reported in both groups, with no deaths occurring during the trial.

This study suggests that mirabegron therapy did not significantly impact LVH or diastolic function in patients with structural heart disease and no or mild HF symptoms.

Reference: Balligand J, Brito D, Brosteanu O, et al. Repurposing the β3-Adrenergic Receptor Agonist Mirabegron in Patients With Structural Cardiac Disease: The Beta3-LVH Phase 2b Randomized Clinical Trial. JAMA Cardiol. Published online September 20, 2023. DOI:10.1001/jamacardio.2023.3003

Full View

Article Source : JAMA Cardiology

Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.

NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.

Isra Zaman

Isra Zaman is a Life Science graduate from Daulat Ram College, Delhi University, and a postgraduate in Biotechnology from Amity University. She has a flair for writing, and her roles at Medicaldialogues include that of a Sr. content writer and a medical correspondent. Her news pieces cover recent discoveries and updates from the health and medicine sector. She can be reached at editorial@medicaldialogues.in.

Comments Policy

Our comments section is governed by our Comments Policy . By posting comments at Medical Dialogues you automatically agree with our Comments Policy , Terms And Conditions and Privacy Policy .

Mirabegron therapy does not prevent progression to Heart Failure: Study

Similar News

Weight Loss Drugs May Lower Risk of Heart Failure Hospitalization and Death by 40 Percent: Study

Is Your Mental Health Putting Your Heart at Risk? Study Sheds Light

No Benefit of Beta Blockers in Certain Heart Attack Patients: REBOOT Trial Finds

Study Reveals Potassium-Rich Foods May Lower Irregular Heartbeat Risk

Study Reveals Daily Intake of Five Mushrooms May Reduce Alzheimer's and Heart Disease Risk

Depression And Schizophrenia Double Heart Disease And Mortality Risks: Lancet Report

How Dangerous Is Irregular Sleep for Heart Failure Survivors? Study Finds Out

This Diet May Cut Risk of Cancer and Heart Disease Multimorbidity: Study Suggests